GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Epigenomics ECX.F · EUR

Health Care · Frankfurt · 🇩🇪 Germany

Compare

0.87

0.00%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in EUR, from our data supplier.

FY2024

Revenue

—

FY2015FY2024

Net income

−€3.4m

FY2015FY2024

Free cash flow

−€1.2m

FY2015FY2024

Shareholders' equity

—

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue—€339,200€899,000€6.2m€842,000€1.1m€1.5m€1.9m€4.2m€2.1m
Research and development——€6.2m€3.1m€3.7m€7.3m€6.4m€4.3m€5.1m€5.8m
Operating income−€1.1m−€7.6m−€11.7m−€2.4m−€10.1m−€15.1m−€13.3m−€9.9m−€12.4m−€9.3m
Net income−€3.4m−€4.5m−€17.3m−€2.4m−€11.7m−€17.0m−€12.7m−€10.2m−€11.2m−€9.0m
Diluted earnings per share-3.82-5.23-21.28-0.05-0.50-0.90-0.90-3.15-3.92-3.74

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assets€11.9m€12.8m€14.0m€24.7m€6.8m€14.0m€21.8m€19.8m€18.2m€12.6m
Cash and short-term investments€927,000€2.1m€7.8m€23.0m€4.4m€11.0m€17.1m€13.7m€12.3m€8.6m
Total liabilities€11.9m€12.8m€14.0m€2.5m€2.9m€4.4m€3.2m€9.2m€3.8m€5.5m
Debt€11.4m€11.9m€12.7m€460,000€683,000€913,000€653,000€6.5m€753,000€1.1m
Shareholders' equity———€22.1m€3.9m€9.6m€18.6m€10.6m€14.4m€7.1m
Shares outstanding1m1m1m45m24m19m14m3m3m2m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations−€1.2m−€5.7m−€10.6m−€4.2m−€9.6m−€13.5m−€10.4m−€9.6m−€13.3m−€8.1m
Capital spending—−€3,000−€138,000−€35,000−€21,000−€122,000−€106,000−€583,000−€1.3m−€213,000
Free cash flow−€1.2m−€5.7m−€10.8m−€4.2m−€9.6m−€13.6m−€10.5m−€10.2m−€14.6m−€8.3m

Latest quarters

By quarter end

Jun 2025Dec 2024Jun 2024Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022
Revenue€4,000——€70,000€134,000€99,000€145,000€126,000
Operating income−€208,000−€488,000−€643,000−€2.8m−€5.7m−€2.9m−€1.5m−€1.3m
Net income−€204,000−€2.6m−€796,000−€2.6m−€5.6m−€6.5m−€1.6m−€1.3m
Diluted earnings per share-0.23-2.91-0.91-3.09-6.55-7.95-0.02-0.02
Cash from operations——————−€2.0m−€2.0m
Total assets€11.9m€11.9m€12.0m€4.2m€11.1m€15.9m€19.0m€20.6m
Cash and short-term investments€764,000€927,000€1.2m€3.6m€6.9m€10.0m€15.8m€18.0m
Debt€11.4m€11.4m€11.4m€124,000€184,000€517,000€966,000€1.0m
Shareholders' equity———€1.9m€4.5m€10.2m€13.9m€16.7m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-21.7%-40.4%-17.2%
Net income11.3%-27.7%-8.3%

Valuation history

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Price to earnings-0.2-0.1-0.1-53.1-27.9-17.4-20.5-8.7-7.3-3.9
Price to sales—1.71.620.8387.4262.7169.548.019.516.9

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 5-to-1 reverse split · 8 Dec 2023
  • 4-to-1 reverse split · 27 Dec 2022
  • 8-to-1 reverse split · 11 Dec 2020
  • 1-to-1 reverse split · 22 Sept 2014
  • 5-to-1 reverse split · 8 Aug 2011

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.